DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-196/S-012

Jazz Pharmaceuticals, Inc.
ATTENTION: Jennifer Ekelund
Senior Director, Regulatory Affairs
3180 Porter Drive
Palo Alto, CA 94304

Dear Ms. Ekelund:

Please refer to your supplemental new drug application dated August 17, 2006, received August 18, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Xyrem (sodium oxybate) oral solution 500 mg/mL.

We acknowledge receipt of your submissions dated September 6, 2006, September 22, 2006 and October 17, 2006.

This supplemental new drug application provides for the Patient Enrollment Form, Prescription Form and Physician Registration Form.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (Patient Enrollment Form, Prescription Form, and Physician Registration Form submitted September 22, 2006).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submissions "**FPL for approved supplement NDA 21-196/S-012**." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Jacqueline Ware, PharmD, Senior Regulatory Project Manager, at (301) 796-2250.

Sincerely,

{See appended electronic signature page}

Russell Katz, MD
Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Russell Katz
11/13/2006 03:29:53 PM